Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | CES2 | O00748 | 1/20 | 0.32 |
| ▸ | CES1 | P23141 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | PHGDH | O43175 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2476289 | 1.00 | GSK3B (0.32) | GSK3BCES2CES1ALOX15TSHR | |
| SCHEMBL8718920 | 0.90 | HPGD (0.33) | CES2CES1MEN1KMT2AGAA | |
| SCHEMBL2471234 | 0.90 | HPGD (0.33) | CES2CES1MEN1KMT2AGAA | |
| SCHEMBL6142770 | 0.90 | HPGD (0.33) | CES2CES1MEN1KMT2AGAA | |
| SCHEMBL8112010 | 0.86 | KMT2A (0.33) | GSK3BCES2CES1MEN1KMT2A | |
| SCHEMBL8112015 | 0.86 | KMT2A (0.33) | GSK3BCES2CES1MEN1KMT2A | |
| SCHEMBL1799677 | 0.80 | HPGD (0.33) | CES2CES1MEN1KMT2AGAA | |
| SCHEMBL8044926 | 0.78 | P2RX7 (0.32) | GSK3BCES2CES1ALOX15TSHR | |
| SCHEMBL9594501 | 0.78 | P2RX7 (0.32) | GSK3BCES2CES1ALOX15TSHR | |
| SCHEMBL11350296 | 0.78 | P2RX7 (0.32) | GSK3BCES2CES1ALOX15TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9266863-B2 | Process for the synthesis of azacitidine and decitabine | CHEMI SPA (IT) | 2016-02-23 | — | — | US | claimed |
| EP-2371825-B1 | Process for the synthesis of azacitidine and decitabine | CHEMI SPA (IT) | 2014-01-08 | — | — | EP | claimed |
| US-20110245485-A1 | PROCESS FOR THE SYNTHESIS OF AZACITIDINE AND DECITABINE | CHEMI SPA (IT) | 2011-10-06 | — | — | US | claimed |
| EP-2371825-A1 | Process for the synthesis of azacitidine and decitabine | Chemi SPA (IT) | 2011-10-05 | — | — | EP | claimed |
| US-9266863-B2 | Process for the synthesis of azacitidine and decitabine | CHEMI SPA (IT) | 2016-02-23 | — | — | US | disclosed |
| EP-2371825-B1 | Process for the synthesis of azacitidine and decitabine | CHEMI SPA (IT) | 2014-01-08 | — | — | EP | disclosed |
| US-20110245485-A1 | PROCESS FOR THE SYNTHESIS OF AZACITIDINE AND DECITABINE | CHEMI SPA (IT) | 2011-10-06 | — | — | US | disclosed |
| EP-2371825-A1 | Process for the synthesis of azacitidine and decitabine | Chemi SPA (IT) | 2011-10-05 | — | — | EP | disclosed |
| CN-101948493-A | Industrial production method of high-purity decitabine | JIANGSU AOSAIKANG PHARM CO LTD | 2011-01-19 | — | — | CN | disclosed |
| JP-2000290289-A | PRODUCTION OF 1-HALOGENO-2-DEOXYRIBOFURANOSE DERIVATIVE | MITSUI CHEMICALS INC | 2000-10-17 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245485-A1 | PROCESS FOR THE SYNTHESIS OF AZACITIDINE AND DECITABINE | DNMT1, TET1, TET2 | GSK3B 1217/4885CES2 982/4885CES1 1620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.